Should testosterone replacement be offered to hypogonadal men treated previously for prostatic carcinoma?
Clin Endocrinol (Oxf)
; 76(2): 179-81, 2012 Feb.
Article
en En
| MEDLINE
| ID: mdl-21951017
Androgen administration can cause prostate cancer progression, and androgen deprivation therapy is a commonly used therapeutic modality in the treatment of prostate cancer. In trying to answer the posed clinical question, this article reviews the risks and benefits of testosterone replacement therapy in this setting and the published data from clinical series. Recommendations are made based on the available evidence.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Testosterona
/
Terapia de Reemplazo de Hormonas
/
Hipogonadismo
Tipo de estudio:
Guideline
Límite:
Humans
/
Male
Idioma:
En
Revista:
Clin Endocrinol (Oxf)
Año:
2012
Tipo del documento:
Article
Pais de publicación:
Reino Unido